Full dose of iNTS-TCV
Phase 2Biologic
GSKFull dose of iNTS-TCV is one of 4 biologic programs targeting Typhoid Fever. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Typhoid Fever
#DrugCompanyPhaseTrials
1Merrem
BB. Braun Medical Inc.
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Full dose of iNTS-TCV
GSKPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Full dose of iNTS-TCV. EMBL-EBI & Wellcome Sanger Institute.
- [4]